PTC-209 (hydrobromide)

CAT: 0804-HY-15888A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15888A-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs) . PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment[1][2].
CAS Number
[1217022-63-3]
UNSPSC
12352005
Target
Autophagy; BMI1
Type
Reference compound
Related Pathways
Autophagy; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PTC-209-hydrobromide.html
Purity
99.02
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(C2=CSC(NC3=C(Br)C=C(OC)C=C3Br)=N2)N4C=CC=NC4=N1.Br
Molecular Formula
C17H14Br3N5OS
Molecular Weight
576.10
References & Citations
[1]Kreso A, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20 (1) :29-36.|[2]Christian Mayr, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016 Jan 5; 7 (1) : 745-758.|[3]Shahi MH, et al. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance. PLoS One. 2015 Jun 25;10 (6) :e0131006.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products